Generalized anxiety disorder does not arrive with sudden outbursts or fainting in the supermarket. It arrives as a constant rain of worries.… Read more.
8 factors with evidence, ordered from highest to lowest effectiveness. Information, not medical advice.
⏱ 3 min read
Generalized anxiety disorder does not arrive with sudden outbursts or fainting spells in the supermarket. It arrives as a constant rain of worries. The mind looks for problems to solve even when there are none: if there is no real reason to worry about health, it worries about what others will say, and if there is nothing of that either, it worries about worrying. People with GAD describe an almost permanent state of inner restlessness, unable to rest. What is characteristic is not the worry itself, which is human, but that it is excessive, uncontrollable, and out of proportion to the real problem.
In many cases, GAD goes unnoticed for years because the person interprets it as "that's just how I am," as personality, as tiredness, or as lack of character. Physical symptoms (muscle tension, tension headaches, functional digestive problems, sleep-maintenance insomnia, fatigue) are often the reason for the visit, rather than the worry itself. Blood work is ordered, it comes back normal, and an as-needed anxiolytic is prescribed without addressing the root. Lifetime prevalence is around 5-9% of the population, with a female predominance of roughly 2 to 1, and it usually begins in late adolescence or the twenties.
In GAD the key brain circuit connects the amygdala, insula, medial prefrontal cortex, and striatum. The amygdala is hyperreactive to ambiguous stimuli (that odd look from the boss, that unanswered message), and the ventromedial prefrontal cortex, which normally puts on the brakes, shows lower functional connectivity. The result is a system that activates easily and shuts off with difficulty. On the biochemical level, GABA is functionally hypoactive, serotonin is dysregulated, and norepinephrine is hyperactive, which explains why the treatments with the best evidence act on these three pathways: SSRIs as first line, benzodiazepines for occasional use (with caution because of dependence), and, in the nutraceutical world, Silexan and kava for their GABAergic action.
Silexan (oral lavender essential oil, 80-160 mg/day) is the supplement with the best evidence in GAD, with efficacy comparable to paroxetine 20 mg in the most recent meta-analysis (PMID 36717399), without daytime sedation, without dependence, and with an excellent tolerability profile. Kava has solid evidence from a Cochrane meta-analysis (PMID 14584033) but requires aqueous extracts of noble root and short periods because of the documented hepatotoxic risk. Standardized chamomile has the 2009 Amsterdam trial (PMID 19593179) with a significant reduction in HAM-A vs placebo at 8 weeks, and a 38-week maintenance trial confirming a lower relapse rate. Ashwagandha provides a milder, more global anxiolytic effect (stress + sleep + energy), useful as an adjunct. Magnesium glycinate, passionflower, and L-theanine complete the list of safe interventions.
No biochemical intervention sustains improvement in GAD over the long term if the person does not relearn how to relate to uncertainty. Cognitive behavioral therapy with worry exposure and cognitive restructuring are the first-line psychotherapies, with solid evidence and response rates of 60-70%. Acceptance and commitment therapy (ACT) teaches people to make room for worry without letting it govern behavior, and in many patients with a rigid or perfectionist profile it is more effective than classic CBT. IFS is useful when the anxiety has traumatic roots and there is a "protective part" that stays on watch to avoid old suffering.
What a person with GAD eats, how they sleep, how much they move, and how they breathe changes the ceiling of possible improvement. Slow resonance breathing (5.5 breaths per minute for 5 minutes, 3 times a day) raises vagal tone and lowers anxious reactivity. Aerobic exercise ≥150 min/week has an anxiolytic effect comparable to that of an SSRI at a medium dose according to recent meta-analyses. Regular sleep (≥7 hours, a consistent bedtime), morning sunlight, and limiting caffeine after 2 p.m. are small adjustments with a large impact. Reducing alcohol is especially important: the immediate sense of calm it produces is paid for hours later with rebound anxiety.
If worry takes up more than half the day, if insomnia lasts more than two weeks, if the person starts avoiding situations they used to manage, or if compensatory behaviors appear (alcohol, shopping, food, screens), there is no need to wait. GAD responds well to structured treatment, and the sooner it is addressed, the better the prognosis.
⏱ 3 min read
Generalized anxiety disorder does not arrive with sudden outbursts or fainting spells in the supermarket. It arrives as a constant rain of worries. The mind looks for problems to solve even when there are none: if there is no real reason to worry about health, it worries about what others will say, and if there is nothing of that either, it worries about worrying. People with GAD describe an almost permanent state of inner restlessness, unable to rest. What is characteristic is not the worry itself, which is human, but that it is excessive, uncontrollable, and out of proportion to the real problem.
In many cases, GAD goes unnoticed for years because the person interprets it as "that's just how I am," as personality, as tiredness, or as lack of character. Physical symptoms (muscle tension, tension headaches, functional digestive problems, sleep-maintenance insomnia, fatigue) are often the reason for the visit, rather than the worry itself. Blood work is ordered, it comes back normal, and an as-needed anxiolytic is prescribed without addressing the root. Lifetime prevalence is around 5-9% of the population, with a female predominance of roughly 2 to 1, and it usually begins in late adolescence or the twenties.
In GAD the key brain circuit connects the amygdala, insula, medial prefrontal cortex, and striatum. The amygdala is hyperreactive to ambiguous stimuli (that odd look from the boss, that unanswered message), and the ventromedial prefrontal cortex, which normally puts on the brakes, shows lower functional connectivity. The result is a system that activates easily and shuts off with difficulty. On the biochemical level, GABA is functionally hypoactive, serotonin is dysregulated, and norepinephrine is hyperactive, which explains why the treatments with the best evidence act on these three pathways: SSRIs as first line, benzodiazepines for occasional use (with caution because of dependence), and, in the nutraceutical world, Silexan and kava for their GABAergic action.
Silexan (oral lavender essential oil, 80-160 mg/day) is the supplement with the best evidence in GAD, with efficacy comparable to paroxetine 20 mg in the most recent meta-analysis (PMID 36717399), without daytime sedation, without dependence, and with an excellent tolerability profile. Kava has solid evidence from a Cochrane meta-analysis (PMID 14584033) but requires aqueous extracts of noble root and short periods because of the documented hepatotoxic risk. Standardized chamomile has the 2009 Amsterdam trial (PMID 19593179) with a significant reduction in HAM-A vs placebo at 8 weeks, and a 38-week maintenance trial confirming a lower relapse rate. Ashwagandha provides a milder, more global anxiolytic effect (stress + sleep + energy), useful as an adjunct. Magnesium glycinate, passionflower, and L-theanine complete the list of safe interventions.
No biochemical intervention sustains improvement in GAD over the long term if the person does not relearn how to relate to uncertainty. Cognitive behavioral therapy with worry exposure and cognitive restructuring are the first-line psychotherapies, with solid evidence and response rates of 60-70%. Acceptance and commitment therapy (ACT) teaches people to make room for worry without letting it govern behavior, and in many patients with a rigid or perfectionist profile it is more effective than classic CBT. IFS is useful when the anxiety has traumatic roots and there is a "protective part" that stays on watch to avoid old suffering.
What a person with GAD eats, how they sleep, how much they move, and how they breathe changes the ceiling of possible improvement. Slow resonance breathing (5.5 breaths per minute for 5 minutes, 3 times a day) raises vagal tone and lowers anxious reactivity. Aerobic exercise ≥150 min/week has an anxiolytic effect comparable to that of an SSRI at a medium dose according to recent meta-analyses. Regular sleep (≥7 hours, a consistent bedtime), morning sunlight, and limiting caffeine after 2 p.m. are small adjustments with a large impact. Reducing alcohol is especially important: the immediate sense of calm it produces is paid for hours later with rebound anxiety.
If worry takes up more than half the day, if insomnia lasts more than two weeks, if the person starts avoiding situations they used to manage, or if compensatory behaviors appear (alcohol, shopping, food, screens), there is no need to wait. GAD responds well to structured treatment, and the sooner it is addressed, the better the prognosis.